



(11) **EP 4 041 713 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
15.01.2025 Bulletin 2025/03

(45) Date of publication and mention
of the grant of the patent:
11.12.2024 Bulletin 2024/50

(21) Application number: **20800444.0**

(22) Date of filing: **09.10.2020**

(51) International Patent Classification (IPC):
C07D 217/04 ^(2006.01) **A61P 25/08** ^(2006.01)
A61K 31/472 ^(2006.01)

(52) Cooperative Patent Classification (CPC):
C07D 217/04; A61P 25/08

(86) International application number:
PCT/US2020/055129

(87) International publication number:
WO 2021/072307 (15.04.2021 Gazette 2021/15)

(54) **SOLID STATE CRYSTALLINE FORMS OF A SELECTIVE POTASSIUM CHANNEL MODULATOR**
FESTE KRISTALLINE FORMEN EINES SELEKTIVEN KALIUMKANALMODULATORS
FORMES CRISTALLINES À L'ÉTAT SOLIDE D'UN MODULATEUR SÉLECTIF DU CANAL
POTASSIQUE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **10.10.2019 US 201962913574 P**

(43) Date of publication of application:
17.08.2022 Bulletin 2022/33

(60) Divisional application:
24211142.5

(73) Proprietor: **Xenon Pharmaceuticals Inc.**
Burnaby, BC V5G 4W8 (CA)

(72) Inventors:
• **BICHLER, Paul Robert**
Fernie, British Columbia V0B 1M0 (CA)
• **CADIEUX, Jean-Jacques A.**
Burnaby, British Columbia V5A 4Z2 (CA)
• **TANDY, Matthew David**
Vancouver, British Columbia V5M 1Z3 (CA)

• **BEATCH, Gregory N.**
Vancouver, British Columbia V7W 2H8 (CA)

(74) Representative: **J A Kemp LLP**
80 Turnmill Street
London EC1M 5QU (GB)

(56) References cited:
WO-A2-2008/024398 US-A1- 2011 003 850

• **MINO R CAIRA ED - MONTCHAMP JEAN-LUC:**
"Crystalline Polymorphism of Organic
Compounds", TOPICS IN CURRENT
CHEMISTRY; [TOPICS IN CURRENT
CHEMISTRY], SPRINGER, BERLIN, DE, vol. 198,
January 1998 (1998-01-01), pages 163 - 208,
XP008166276, ISSN: 0340-1022, [retrieved on
19990226], DOI: 10.1007/3-540-69178-2_5
• **STEPHEN BYRN ET AL: "Pharmaceutical Solids:**
A Strategic Approach to Regulatory
Considerations", PHARMACEUTICAL
RESEARCH, vol. 12, no. 7, January 1995
(1995-01-01), pages 945 - 954, XP055531015, DOI:
10.1023/A:1016241927429

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 4 041 713 B8